Infliximab was more effective than azathioprine in reducing histological, but not endoscopic and clinical recurrence after curative ileocolonic resection in "high risk" CD patients.

No abstract

Background and Aims Our first objective was to evaluate the immune response to the adjuvanted 2009 A/H1N1 pandemic (pH1N1) vaccine in inflammatory bowel disease (IBD) patients treated with anti-TNF-α alone or combined with immunosuppressants (IS). Second and third aims were the safety of pH1N1 vaccine and the effects on IBD clinical activity. Methods 36 patients with Crohn's disease (CD) and 26 with ulcerative colitis (UC) and thirty-one healthy control subjects (HC) were enrolled. 47 patients were on anti TNF-α maintenance monotherapy and 15 on anti TNF-α combined with IS. Sera were collected at baseline (T0) and 4 weeks after the vaccination (T1) for antibody determination by hemagglutination inhibition (HAI Disease activity was monitored at T0 and T1. Results Seroprotective titers (≥ 1: 40) in patients were comparable to HC. Seroconvertion rate (≥ 4 fold increase in HAI titer) was lower than HC in IBD patients (p=0,009), either on anti TNF-α monotherapy (p=0,034) or combined with IS (p=0,011). Geometric mean titer (GMT) of antibodies at T1 was significantly lower in patients on combined therapy versus those on monotherapy (p=0,0017) and versus HC (p=0,011). The factor increase of GMT at T1 versus T0 was significantly lower in IBD patients versus HC (p=0,042), and in those on combined immunosuppression, both versus monotherapy (p=0,0048) and HC (p=0,0015). None of the patients experienced a disease flare. Conclusion Our study has shown a suboptimal response to pH1N1 vaccine in IBD patients on therapy with anti TNF-α and IS compared to those on anti-TNF-α monotherapy and HC.

HBV and HCV infection rates were similar to infection rates among the general population. Less than one quarter of the patients had been vaccinated against HBV. Anti-TNF-α agents appear to be safe for patients with HBV infection; more data are needed for patients with HCV infection.

Background and aim: Optical diagnosis (OD) of colonic polyps is poorly reproducible outside high-volume referral centres. Present study aimed to assess whether real-time AI-assisted OD is accurate enough to implement the leave-in-situ strategy for diminutive (5mm) rectosigmoid (DRSPs) polyps. Methods: Consecutive colonoscopy outpatients with 5mm) rectosigmoid (DRSPs) polyps. Methods: Consecutive colonoscopy outpatients with >1 DRSP were included. DRSPs were categorized as adenomas or non-adenomas by the endoscopist, with different expertise in OD, with the assistance of real-time AI system (CADEYE, Fujifilm Co., Tokyo-Japan). Primary study endpoint was >90% negative predictive value (NPV) for adenomatous histology in high-confidence AI-assisted OD of DRSPs (Preservation and Incorporation of Valuable endoscopic Innovations (PIVI-1) threshold), with histopathology as reference standard. The agreement between optical- and histology-based post-polypectomy surveillance intervals (>90%, PIVI-2 threshold) was also calculated according to European Society of Gastrointestinal Endoscopy (ESGE) and United States Multi-Society Task Force (USMSTF) guidelines. Results: Overall 596 DRSPs were retrieved for histology in 389 patients; AI-assisted high-confidence OD was made in 92.3%. The NPV of AI-assisted OD for DRSPs (PIVI-1) was 91.0% (95%CI [87.1-93.9]%). PIVI-2 threshold was met in 97.4% (95%CI [95.7-98.9]%) and 92.6% (95%CI [90.0-95.2]%) of patients according to ESGE and USMSTF, respectively. The AI-assisted OD accuracy was significantly lower for non-experts (82.3%; 95% CI [76.4-87.3]%) than for experts (91.9%; 95%CI [88.5-94.5]%), however non-experts in OD quickly approached experts’ performances over time. Conclusion: AI-assisted OD matches the required PIVI thresholds. However, this does not offset the need for a high-level confidence and expertise by the endoscopist. The AI system seems to be useful especially for non-experts.

No abstract

Crohn’s disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory bowel disease (IBD), are chronic inflammatory conditions, characterized by a microvascular and also macrovascular involvement. Chronically inflamed intestinal microvessels of IBD patients have demonstrated significant alterations in their physiology and function compared with vessels from healthy and uninvolved IBD intestine. Recently, some studies have revealed that the poor mucosal healing, refractory inflammatory ulcerations and damage in the IBD intestine could depend on microvascular dysfunction, resulting in diminished vasodilatory capacity and tissue hypoperfusion in the IBD gut. Furthermore, several data show that the activation of intestinal endothelium plays a critical role in the pathogenesis and/or in perpetuating and amplifying the inflammatory process in IBD and, consequently, it is now emerging as a potential use of anticoagulant or coagulation-related drugs in treating IBD. IBD is also associated with an increased risk of macrovascular venous and arterial thrombosis. Thrombotic events occur prevalently as deep vein thrombosis and pulmonary embolism. They happen at an earlier age than in non-IBD patients. Prothrombotic risk factors in IBD patients could be distinguished as acquired, such as active inflammation, immobility, surgery, steroid therapy, and use of central venous catheters, and inherited. Furthermore, it has been found that IBD, per se, is an independent risk factor for thrombosis. The prevention of thromboembolic events in IBD patients includes the elimination of removable risk factors and, if thrombosis occurs, a pharmacological therapy similar to that used for thromboembolic events occurring in the general population.

Long-term IFX treatment is effective in inducing sustained clinical response in patients with steroid-dependent UC. Combination therapy is predictive of sustained clinical response in the long-term. Patients with more severe endoscopic lesions at baseline and high C-reactive protein after induction are at higher risk of colectomy. Conversely, thiopurine naive status is protective from colectomy.